Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin and Sitagliptin Clear all
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

NCT02956044
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Metformin, Glimepiride, Sitagliptin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 30, 2026, 2:50 PM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

NCT01475461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 30, 2026, 2:50 PM EDT
Not listed No phase listed Observational

Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

NCT00790348
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

NCT00751114
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

NCT04409795
View directory record Official record
Conditions
Type 1 Diabetes, Monogenic Diabetes
Interventions
Metformin Extended Release Oral Tablet, Sitagliptin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
Up to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 30, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 30, 2026, 2:50 PM EDT
Completed No phase listed Observational Results available

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

NCT01077323
View directory record Official record
Conditions
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
Interventions
exenatide, Other antidiabetic therapies, No diabetes therapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
363,766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

NCT00734474
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
35
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

NCT00789191
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, sitagliptin, metformin, sulphonylurea
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 30, 2026, 2:50 PM EDT
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 4 Interventional

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

NCT01718093
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin, Metformin, Sitagliptin + Metformin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Sep 30, 2026, 2:50 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

NCT01089790
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dutogliptin, Sitagliptin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 86 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
149
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738
View directory record Official record
Conditions
Diabetes, Type 2
Interventions
Placebo, 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

NCT00729326
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Metformin, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 30, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

NCT00851903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 71 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 30, 2026, 2:50 PM EDT